Human Herpesvirus 8 Interleukin-6 (vIL-6) Signals through gp130 but Has Structural and Receptor-Binding Properties Distinct from Those of Human IL-6

XIAOYU WAN, HAILIN WANG, AND JOHN NICHOLAS*

Molecular Virology Laboratories, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231

Received 26 March 1999/Accepted 17 June 1999

Human herpesvirus 8 (HHV-8) has been associated with classical, endemic (African), and AIDS-related Kaposi’s sarcoma (KS), body cavity-based primary effusion lymphomas, and multicentric Castleman’s disease (MCD). HHV-8 encodes a functional homologue of interleukin-6 (IL-6), a cytokine that promotes the growth of KS and myeloma cells and is found at elevated levels in MCD lesions and patient sera. We have previously reported that the viral IL-6 (vIL-6) gene product can support the growth of the IL-6-dependent murine hybridoma cell line, B9, and that the gp80 (IL-6 receptor [IL-6R]) component of the IL-6 receptor-signal transducer (gp180) complex plays a role in mediating this activity. However, it has been shown by others that vIL-6 can function in human cells independently of IL-6R. Here we have extended our functional studies of vIL-6 by identifying transcription factors and pathways used in human Hep3B cells, investigating the utilization of gp130 and IL-6R by vIL-6, and undertaking mutational analyses of vIL-6 and gp130. The data presented here establish that vIL-6, in common with its endogenous counterparts, can mediate signal transduction through gp130 and activate multiple transcription factors, map residues within the vIL-6 protein that are and are not important for vIL-6 signalling, and identify a gp130 mutant that is nonfunctional with respect to vIL-6 signalling in the absence of IL-6R but that retains the ability to mediate vIL-6 and human IL-6 (hIL-6) signal transduction when IL-6R is coexpressed. The data presented demonstrate functional and mechanistic similarities between vIL-6 and endogenous IL-6 proteins but also highlight differences in the structural and receptor-binding properties of vIL-6 relative to its human counterpart.

Human herpesvirus 8 (HHV-8) is the most recently discovered human herpesvirus; sequences of the virus were originally identified through the application of representational difference analysis applied to Kaposi’s sarcoma (KS) and non-KS tissue (10). HHV-8 DNA was subsequently detected in KS lesions of all types (16, 24, 54), in body cavity-based primary effusion lymphoma (BCBL; PEL) (9), and in multicentric Castleman’s disease (MCD) (58). More recently there have been reports that HHV-8 may also be associated with multiple myeloma (7, 44, 45).

The genomes of two strains of HHV-8 have been sequenced, and the resulting data have demonstrated that HHV-8 is a gamma-2 herpesvirus closely related to herpesvirus saimiri (37, 47). Despite their general colinearity, however, there are major regions of divergence between HHV-8 and herpesvirus saimiri, as there are between gammaherpesvirus genomes in general, and one of these loci, divergent locus B (DL-B), in HHV-8 contains a unique cluster of genes that includes a functional homologue of interleukin-6 (IL-6), vIL-6, that is able to support the growth of the IL-6-dependent murine B9 hybridoma cell line and human myeloma cells and to induce acute-phase gene expression and STAT activation in hepatic cell lines (8, 36, 38, 39, 47). The presence of vIL-6 in HHV-8 is significant because of the potential role of IL-6 in the development and progression of human diseases with which HHV-8 has been associated. IL-6 promotes the growth of KS and myeloma cells and is found at elevated levels in MCD lesions and patient sera.

*Corresponding author. Mailing address: Molecular Virology Laboratories, Department of Oncology, Johns Hopkins University School of Medicine, 418 N. Bond St., Baltimore, MD 21231. Phone: (410) 550-6801. Fax: (410) 550-6802. E-mail: nichojo@welchlink.welch.jhu.edu.

(27, 28, 33, 62). Furthermore, it has recently been reported that IL-6 is produced by and is an important autocrine growth factor for PEL cells (4).

Endogenous IL-6-mediated activation of acute-phase genes is effected through STAT and C/EBP transcription factors (STAT1, STAT3, and C/EBPβ) that are activated, in response to signal transduction via the gp130 protein (which forms part of the IL-6 receptor), through Janus and mitogen-activated protein kinase pathways, respectively (1, 2, 26, 43). The promoters of the acute-phase genes contain binding sites for C/EBP and STAT transcription factors, for each of which there are several known types with similar DNA binding specificities (C/EBPα through C/EBPδ and STAT1 through STAT6 [25, 40]), and these binding sites are important in the activation of acute-phase genes by IL-6 and other inducers of the acute-phase response (12, 29, 42, 55). The STAT binding site is especially important for induction (29, 55). The specificity of STAT induction by tyrosine phosphorylation is determined by the particular signal transducer used during activation and thus is a reflection of the ability of individual Jak-activated receptor complexes to recruit specific STATs rather than of Jak specificity of STAT activation (25, 26). Signal transduction through gp130 predominantly activates STAT3, although STAT1 also is a target of activated gp130 (2, 25, 26). Studies of vIL-6-mediated activation in human HepG2 hepatoma cells have demonstrated the activation of STAT1 and STAT3 by an apparently IL-6 receptor (IL-6R)-independent mechanism and determined that BAF130 cells expressing gp130 in the absence of IL-6R are responsive to vIL-6 (35).

The motivation for the present study was to further characterize the function of vIL-6 by investigating its ability to induce acute-phase gene expression generally and to activate tran-
cription factors in Hep3B cells and determining similarities and differences of vIL-6 and human IL-6 (hIL-6) with respect to both the receptors used for signal transduction and ligand and receptor structural requirements for signalling. These studies have identified STAT1, STAT3, and C/EBP transcription factors as targets of vIL-6 signalling in Hep3B cells and indicated that gp130 is sufficient for vIL-6 but not hIL-6 signalling. However, the IL-6R component does augment vIL-6 activity and enables signal transduction by vIL-6 through a gp130 variant that is otherwise nonfunctional with respect to vIL-6 signalling and competition of altered forms of vIL-6 specifically mutated in highly conserved residues, some of which are known to be important for hIL-6 function or are present in regions corresponding to receptor binding domains of hIL-6, have provided data suggesting that there are significant differences in the structural requirements of vIL-6 and hIL-6 for receptor binding and signal transduction.

MATERIALS AND METHODS

Cell culture and transfections. Hep3B cells were grown at 37°C as monolayers in Dulbecco modified Eagle medium supplemented with 10% fetal calf serum, 0.1 mM nonessential amino acids, and 1 mM pyruvate. Hep3B cells were passaged 12 to 24 h before transfection to produce monolayers of 40 to 60% confluency in 80-cm² tissue culture flasks. Transfections were carried out by standard methods (49). Plasmids and oligonucleotides.

Plasmids and oligonucleotides. The vIL-6 expression plasmids used contain coding sequences cloned downstream of either the human cytomegalovirus (HCMV) promoter-enhancer (pV-IL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (pvIL6) or the simian virus 40 early promoter-enhancer (p
in common with endogenous IL-6 proteins, can coordinately activate acute-phase gene expression.

**vIL-6 induction of C/EBP and STAT DNA binding activities.**

IL-6 induction of acute-phase gene expression is mediated via activation of factors belonging to the C/EBP and STAT families of transcriptional activators. Specifically, the C/EBPβ (CRP2, NF-IL6) and STAT3 (APRF) proteins have been implicated in the IL-6 signal transduction pathway that is initiated through the gp80/gp130 membrane receptor (1, 2). vIL-6 also induces phosphorylation and activation of STATs, a function that is mediated through gp130 but is not dependent on IL-6R (35). To determine whether vIL-6 could induce C/EBP and STAT activities in Hep3B cells, we performed experiments to identify DNA binding by nuclear proteins to double-stranded C/EBP- or STAT-specific probes (C/EBP-wt and APRF-wt [see Materials and Methods]) containing a consensus binding site for these factors. Hep3B cells were transfected with the vIL-6 expression plasmid pvIL-6 or pSVvIL-6 (38) or with negative controls (pvIL-6neg or pSG5), and the medium from these cultures was harvested to provide sources of vIL-6 or appropriate negative controls. These media were then applied to fresh Hep3B cell cultures for 15 min, and cells were harvested for the preparation of nuclear extracts. These nuclear extracts were used in EMSAs with the 32P-labelled C/EBP-wt or APRF-wt probes. The results of these assays are shown in the left two panels of Fig. 2A and the left panel of Fig. 2B and indicate that C/EBP- and STAT-like DNA binding activities were induced as a function of vIL-6 expression. For C/EBP, the different bands observed in the EMSAs are likely to reflect...
different homodimeric and heterodimeric complexes of C/EBP isoforms (e.g., see references 3 and 61).

To confirm the presence of C/EBP in the shifted complexes, competition assays were carried out with the pSVvIL-6-activated extract (Fig. 2A, middle panel) and unlabelled double-stranded C/EBP oligonucleotide or oligonucleotides corresponding to native (HpxA-wt) or C/EBP-site-altered (HpxA-mut.) versions of -129 to -106 hemopexin A promoter sequences, previously shown to bind C/EBP (42). The results of these assays (Fig. 2A, right) demonstrated that competition

FIG. 3. Characterization of vIL-6-mediated STAT induction in Hep3B cells. (A) Medium containing vIL-6 (from pSVvIL-6-transfected Hep3B cells) or hrIL-6 (500 U/ml) or control medium (fresh or derived from pSG5-transfected Hep3B cells) was applied to serum-starved Hep3B cultures (15 min), and the cells were harvested for the preparation of whole-cell extracts. These extracts were analyzed by Western blot analysis to detect induced (phosphorylated) STAT1 and STAT3 (left and right panels) or total STAT1 (middle panel; stripped, reprobed PY-STAT1 blot). (B) Various dilutions of pSVvIL-6-transfected cell medium were tested for STAT3-inducing activity. Levels of induced STAT3 (top panel) and total STAT3 (bottom panel) in Hep3B cell cultures treated with pSVvIL-6 (1 to 1/16) or pSG5 (0) transfected cell medium were determined by Western analysis. (C) The amount of vIL-6 present in the vIL-6-transfected cell medium was determined by dot blot analysis with a vIL-6 peptide antiserum (see Materials and Methods). The signal from 3 ml of undiluted vIL-6 stock (corresponding to the maximum amount of vIL-6 used for STAT3 induction in panel B) was compared to signals obtained from a dilution series of purified GST-vIL-6 fusion protein to determine the amount of vIL-6 present. The calculated amounts of the vIL-6 component of the GST-vIL-6 fusion protein at each dilution is indicated. Control medium (from pSG5-transfected Hep3B cells) gave no background signal. Also shown are the results of analyses of the expression of vIL-6 variants 15 and 24 (Table 2) secreted from transfected Hep3B cells. (D) The activity and concentration of bacterially synthesized vIL-6 (see Materials and Methods) were determined by STAT3 induction and dot blot assays analogous to those used for Hep3B-expressed vIL-6. Different amounts (in microliters) of bacterial extract (His6vIL-6) were used for each; amounts (in nanograms) of the vIL-6 component of blotted GST-vIL-6 are indicated.
for formation of the vIL-6-activated and other DNA-protein complexes on the C/EBP-wt probe was dependent on the C/EBP-binding core sequences of the HpxA oligonucleotide, indicating that C/EBP factors are present in the observed complexes.

Analogous competition assays were carried out to confirm the presence of STATs in the APRF-wt–protein complexes. These complexes could be competed with a 100-fold excess of unlabelled APRF competitor (APRF-wt), but not with an altered version (APRF-mut.) containing alterations in the STAT recognition sequences or with the C/EBP-wt oligonucleotide that contains unrelated sequences (Fig. 2B, middle). Furthermore, the vIL-6-induced complex comigrated with a complex induced by treatment of cells with rhIL-6 (Fig. 2B, right), indicating that the nuclear factors activated by vIL-6 do indeed represent the same STAT-related factors known to be induced by hIL-6 (2).

Identification of vIL-6-induced STATs. Since several types of STAT transcription factors are known to be present and expressed together in many cell types, we next sought to identify the types of STAT factors induced by vIL-6 in Hep3B cells. Signalling through gp130 can be mediated by a number of cytokines in addition to IL-6, and STAT1 and STAT3 are the STAT factors that are activated by this signal transducer in association with gp130-binding tyrosine kinases.

To determine whether STAT1 and STAT3 were activated in Hep3B cells, we used peptide antisera directed against phosphorylated (activated) STAT1 or STAT3 in Western analyses of extracts of vIL-6- or rhIL-6-treated Hep3B cells. Figure 3A shows the results of one such experiment. Extracts of cells treated with rhIL-6, vIL-6 (derived from pSVvIL-6-transfected Hep3B cells), or negative control medium, comprising either fresh medium without added rhIL-6 or conditioned medium from Hep3B cells transfected with pSG5, were probed for the presence of either phospho-STAT1 (left panel) or phospho-STAT3 (right panel). The blot probed for phospho-STAT1 was stripped and reprobed with STAT1 peptide antiserum to determine the total levels of STAT1 present in each of the cell extracts to confirm equivalent protein loading of the lanes (middle panel). The data shown in Figure 3A are representative of those obtained from several experiments of this type and demonstrate that STAT1 and STAT3 are targets of vIL-6 signal transduction in Hep3B cells. Similar experiments demonstrated that STAT5 was not induced by vIL-6 or hIL-6 (data not shown); STAT5 is not activated through gp130.

Medium containing vIL-6, derived from Hep3B cell cultures transfected with pSVvIL-6, was used at various dilutions to determine the amount required to induce STAT3 phosphorylation in fresh Hep3B cells (Fig. 3B) and was also analyzed by dot blot procedures to quantify the amount of vIL-6 present in the conditioned medium (Fig. 3C). vIL-6 protein was detected by a vIL-6 peptide rabbit antiserum (see Materials and Methods), and quantitation of the amount of vIL-6 present in the conditioned medium was made possible by inclusion on the blot of a dilution series of purified GST–vIL-6 fusion protein as a standard. The results of this analysis showed that vIL-6 present at less than 0.2 ng/ml (the lowest dilution of vIL-6 stock used) was sufficient to effect detectable STAT3 induction in Hep3B cells, as measured by Western analysis of cell extracts (Fig. 3B). Higher levels of phosphorylated STAT3 were detected when vIL-6 was applied at higher doses, with maximum induction being achieved with the highest two concentrations of vIL-6 used (approximately 1.5 and 3.0 ng/ml). By using bacterial cell extracts containing the His6–vIL-6 fusion protein (see Materials and Methods) in analogous STAT3 induction and dot blot assays (Fig. 3D), it was found that the levels of the bacterially produced vIL-6 required to effect STAT3 induction were at least 103-fold higher than the active levels of vIL-6 derived from transfected Hep3B cells.

Utilization of gp130 and IL-6R receptor subunits by vIL-6. To investigate the functional utilization of IL-6R and gp130 by vIL-6, we used IL-6R and gp130 expression vectors and a
promoter-reporter construction, pα2MCAT, comprising sequences of the α2-macroglobulin promoter linked to the chloramphenicol acetyltransferase (CAT) gene (53), in transient-transfection assays. IL-6 and gp130 expression plasmids comprising the respective coding sequences cloned in the powerful eukaryotic expression plasmid pEF-BOS (34) were used in these transfections to ensure very high levels of receptor expression in transfected cells, thereby minimizing potential effects of the naturally expressed receptors in Hep3B cells. Hep3B cells were cotransfected with pα2MCAT together with pEF-BOS, pEFBOS–IL-6R, pEFBOS-gp130, or pEFBOS–IL-6R plus pEFBOS-gp130 in the absence or presence of vIL-6 or hIL-6 (produced from cotransfected pSVvIL-6 and pSVhIL-6; pSG5 was used as the negative control). Cells were subsequently harvested for determinations of relative CAT activities in cell extracts to determine the contribution of each of the receptor components to signalling by vIL-6 and hIL-6. The results of these experiments, performed in duplicate, are shown in Fig. 4. The results obtained in the pSVvIL-6 cotransfection experiments demonstrated that vIL-6 could effect signalling through gp130 in the absence of cotransfected IL-6R, in contrast to hIL-6, which required the coexpression of transfected gp130 and IL-6R. These results indicate that vIL-6, but not hIL-6, can signal independently of IL-6R. While we cannot exclude, on the basis of these data, the formal possibility that the low endogenous levels of IL-6R expressed in Hep3B cells were required for vIL-6 signalling through overexpressed (transfected) gp130, the inability of hIL-6 to signal under the same conditions argues strongly against this possibility (also see below). The presence of overexpressed IL-6R together with gp130 in these assays led to an increase (between two- and fivefold) in the activation of pα2MCAT by vIL-6, suggesting that functional vIL-6–gp130–IL-6R complexes may form and enhance vIL-6 signalling through gp130.

Identification of gp130 E-F loop mutation important for vIL-6 signalling. We introduced several mutations onto the cytokine binding domain of gp130 based on the residues in the homologous region of IL-6R known to be important for hIL-6 binding, for interactions of hIL-6/IL-6R with gp130, and for function (48, 60). Four of the alterations introduced into the gp130 coding sequences are detailed in Table 1. The PM1 and PM2 mutations correspond to previously made alterations within the analogous positions of the homologous domain of IL-6R; the IL-6R mutations (at positions 230 and 260 plus 261) lead to decreased IL-6/IL-6R association with gp130 (48, 60). The PM5 and PM7 mutations are in positions within the cytokine binding loops (E-F and B2-C2) of the cytokine binding domain of gp130, whose crystal structure has recently been published (6).

To assay for the functions of the altered gp130 proteins, we again used the pα2MCAT reporter in Hep3B transfection assays. pSVvIL-6 (alone) or pSVhIL-6 plus pEFBOS–IL-6R were cotransfected along with each of the gp130 expression plasmids (pEFBOS-gp130.PM1, pEFBOS-gp130.PM2, pEFBOS-gp130.PM5, and pEFBOS–gp130.PM7), or pEF-BOS (negative control), and pα2MCAT. CAT activities in cell extracts were determined, and fold inductions relative to the pEF-BOS controls were calculated. The data from duplicate experiments are shown in Fig. 5. While the PM1 and PM2 mutations and the B2-C2 loop mutation, PM7, had no significant effect on vIL-6 or hIL-6 signalling, the PM5 mutation led to almost complete abrogation of gp130 signalling in response to vIL-6 (Fig. 5A, left). However, inclusion of IL-6R in the

---

**TABLE 1. Mutations in the gp130 coding sequence**

<table>
<thead>
<tr>
<th>Designation</th>
<th>Position</th>
<th>Residues</th>
<th>Changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>PM1</td>
<td>236–238</td>
<td>LSS</td>
<td>DDD</td>
</tr>
<tr>
<td>PM2</td>
<td>287 and 288</td>
<td>QD</td>
<td>SV</td>
</tr>
<tr>
<td>PM5</td>
<td>190–192</td>
<td>YFV</td>
<td>AAA</td>
</tr>
<tr>
<td>PM7</td>
<td>251 and 252</td>
<td>SV</td>
<td>AA</td>
</tr>
</tbody>
</table>

---

![Fig. 5](http://jvi.asm.org/) Functional properties of gp130 signal transducer variants. Each of the altered gp130 coding sequences (Table 1), cloned in expression vector pEF-BOS, was cotransfected into Hep3B cells with pα2MCAT and either pSG5–vIL-6 (alone) (A, left panel) or pSG5–hIL-6 plus pEFBOS–IL-6R (B). Cells were harvested after 48 h for determinations of CAT activities in cell extracts. Levels of induction were calculated by comparisons with CAT activities obtained from pEF-BOS-transfected cells. The data from duplicate experiments are shown. Similar cotransfection experiments were conducted with gp130.PM5 to investigate the effects of coexpressed IL-6R on signal transduction by vIL-6 (A, right panel).
TABLE 2. Mutated residues in vIL-6

<table>
<thead>
<tr>
<th>Position(s)</th>
<th>Residue(s)</th>
<th>Change(s)</th>
<th>Mutant designation</th>
<th>Activity</th>
<th>Comments</th>
<th>Reference(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13</td>
<td>G</td>
<td>W</td>
<td>1</td>
<td>++ +</td>
<td>Conserved</td>
<td>50, 52</td>
</tr>
<tr>
<td>41, 43</td>
<td>W, L</td>
<td>F, G</td>
<td>19</td>
<td>++ +</td>
<td>Site II, gp130 interactions (hIL-6)</td>
<td>50, 52</td>
</tr>
<tr>
<td>54</td>
<td>C</td>
<td>D</td>
<td>2</td>
<td>++ +</td>
<td>Conserved</td>
<td>50, 52</td>
</tr>
<tr>
<td>60</td>
<td>C</td>
<td>S</td>
<td>4</td>
<td>++ +</td>
<td>Conserved</td>
<td>50, 52</td>
</tr>
<tr>
<td>75</td>
<td>P</td>
<td>S</td>
<td>7</td>
<td>++ +</td>
<td>Conserved</td>
<td>50, 52</td>
</tr>
<tr>
<td>83</td>
<td>C</td>
<td>G</td>
<td>8</td>
<td>++ +</td>
<td>Conserved, functional (hIL-6)</td>
<td>46, 57</td>
</tr>
<tr>
<td>88</td>
<td>F</td>
<td>L</td>
<td>20</td>
<td>++ +</td>
<td>Site I, important for IL-6R binding (hIL-6)</td>
<td>59</td>
</tr>
<tr>
<td>93</td>
<td>C</td>
<td>G</td>
<td>9</td>
<td>++ +</td>
<td>Site I, conserved, functional (hIL-6)</td>
<td>46, 57</td>
</tr>
<tr>
<td>103–105</td>
<td>EFE</td>
<td>EGG</td>
<td>22</td>
<td>++ +</td>
<td>Site I, E-103 conserved, important for IL-6R binding (hIL-6)</td>
<td>59</td>
</tr>
<tr>
<td>129</td>
<td>T</td>
<td>L</td>
<td>11</td>
<td>++ +</td>
<td>Site II, conserved</td>
<td>50, 52</td>
</tr>
<tr>
<td>151</td>
<td>P</td>
<td>F</td>
<td>13</td>
<td>++ +</td>
<td>Conserved</td>
<td>50, 52</td>
</tr>
<tr>
<td>167</td>
<td>W</td>
<td>G</td>
<td>15</td>
<td>+</td>
<td>Site III, conserved</td>
<td>50, 52</td>
</tr>
<tr>
<td>183</td>
<td>F</td>
<td>W</td>
<td>17</td>
<td>++ +</td>
<td>Conserved, F to A in hIL-6 shows reduced cell surface binding</td>
<td>31</td>
</tr>
<tr>
<td>189</td>
<td>R</td>
<td>L</td>
<td>25</td>
<td>++ +</td>
<td>Site I, conserved, positively charged residue at this position in hIL-6 important for binding and activity</td>
<td>20, 31</td>
</tr>
<tr>
<td>195</td>
<td>P</td>
<td>Stop</td>
<td>28</td>
<td>++ +</td>
<td>C-tail deletion, 195–204</td>
<td>20, 31</td>
</tr>
</tbody>
</table>

Mutational analysis of vIL-6 to identify residues important for vIL-6 signal transduction. Detailed mutagenesis and structural studies of hIL-6 have identified the regions and residues of the molecule that are important for receptor interactions and signalling through the IL-6R/gp130 complex (see, e.g., references 5, 17, 23, 41, and 51). Three main functional domains of hIL-6, sites 1, 2, and 3, have been recognized and are involved either in hIL-6 interaction with IL-6R (site 1) or in associations of IL-6/IL-6R with gp130 to effect the assembly of the hexameric, functional ligand-receptor complex (32, 56).

To identify residues within vIL-6 that are functionally important with respect to signalling through induction of STAT transcription factors, we generated a panel of vIL-6 mutants for use in functional assays involving cotransfection of each of the vIL-6 variants with pSG5 into Hep3B cells. Residues targeted for mutagenesis were chosen because they are highly conserved between species or because they correspond to residues in hIL-6 known to be important for interactions with IL-6R or gp130. Thus, many of the mutated residues fall into the regions of vIL-6 corresponding to binding site 1, 2, or 3 of hIL-6 (56) (Table 2).

Mutations were introduced into vIL-6 coding sequences by using the M13-based method of Kunkel (30) (see Materials and Methods). Except for the introduction of a stop codon at position 95 (mutant 28), mutagenesis at each position was performed with degenerate mutagenic primers to enable the introduction of multiple changes at each of the targeted amino acid positions. A total of 16 positions were targeted for mutagenesis, and 28 vIL-6 variants were selected for functional analysis. Each altered vIL-6 open reading frame cloned into pSG5 was sequenced to confirm the presence of the mutation(s). The various mutations that were generated are summarized in Table 2.

Each of the vIL-6 mutant expression vectors was cotransfected with pSG5 into Hep3B cells to compare their activities to native vIL-6 and to each other. The entire panel of vIL-6 mutants was used in two separate experiments (Fig. 6), and the activities of the altered vIL-6 proteins are indicated in Table 2. It is noteworthy that only two of the tested vIL-6 mutants showed significant changes in activity in this assay, although hIL-6 equivalents of many of the targeted residues are known to be important for hIL-6 function. For example, the first and second pair of cysteine residues are involved in disulfide bridging in hIL-6 (11), and such bridging between the third and fourth cysteine residues is important for function (46, 57). However, in vIL-6, disulfide bridging between the conserved cysteine residues is clearly not necessary for function, since each of the four cysteines (C<sub>25</sub>, C<sub>40</sub>, C<sub>55</sub>, and C<sub>82</sub>) could be altered without any significant effect on vIL-6 activity. Similarly, while changes in F<sub>88</sub>, E<sub>103</sub> to E<sub>105</sub>, and R<sub>189</sub> had no effect on vIL-6 function, alterations of equivalent residues in hIL-6, all occurring within site 1, lead to loss of IL-6R binding or function (20, 31, 59). Also, position 183 in vIL-6 contains a highly conserved phenylalanine residue which in hIL-6 is important for high-affinity cell surface binding (31); mutation of this residue in vIL-6 (to W, G, E, or L) had no significant effect on vIL-6 activity (20, 31, 59).
impact on function. Two positions in vIL-6 were identified as being important for functional integrity; these are positions 167 and 172, which lie within a region equivalent to receptor interaction site 3 in hIL-6. When W167 was changed to glycine (mutant 15), the activity of vIL-6 was severely impaired (Fig. 6). An arginine substitution at this position had no significant effect. However, replacement of the arginine at position 172 by proline, together with the R167 substitution (mutant 24), greatly diminished vIL-6 activity. This altered vIL-6 protein corresponds to an hIL-6 mutant (W157T162 to R157P162, numbering from the first residue of the mature, cleaved protein) that is able to bind IL-6R with increased affinity but shows reduced bioactivity, most probably due to a decreased ability to form stable, functional complexes with gp130 (13). Such reduced stability of hIL-6–IL-6R–gp130 hexameric complex formation has been demonstrated for a comparable Q159T162-to-E159P162 hIL-6 variant (14, 22). It is likely that the effects on function of these analogous mutations in vIL-6 and hIL-6 result from similar effects on cytokine-gp130 associations. However, the combined data from our vIL-6 mutagenesis studies indicate that there are fundamental differences in the structures and receptor binding requirements of vIL-6 and hIL-6.

To rule out the possibility that vIL-6 variants 15 and 24 contain alterations other than those specifically introduced, which could account for their decrease activities, each vIL-6 coding sequence was sequenced completely; no unexpected changes were identified. To investigate the possibility that the expressed levels of the secreted proteins were reduced due to decreased stabilities of the altered proteins, the presence and levels of the vIL-6 variants relative to wild-type vIL-6 in the medium of transfected Hep3B cells were determined. This was done by dot blot analysis with our vIL-6 peptide antiserum, with a dilution series of purified GST–vIL-6 fusion protein used as a standard for quantitation. The results of this analysis (Fig. 3C) demonstrated that vIL-6 mutant 15 was present in the culture medium at a concentration (approximately 3 ng/ml) equivalent to that of wild-type vIL-6 whereas mutant 24 was present at a level well in excess of 100 ng/ml. Comparable amounts of vIL-6 variant 24 (measured as nanograms per milliliter and relative to wild-type) were seen consistently in the medium in several independent Hep3B transfection experiments (data not shown); a possible explanation is that the W167 to R and/or the A 172 to P change(s) has a stabilizing effect, allowing greater accumulation of the protein in the culture medium.

**DISCUSSION**

The presence of vIL-6 in HHV-8, a virus that is associated with KS, PEL, and MCD, is significant in view of the findings that cytokines, particularly IL-6, are likely to play a role in the development and progression of these diseases. AIDS-KS cells have been reported to secrete several cytokines, including IL-6, basic fibroblast growth factor, and platelet-derived growth factor; IL-6 and IL-6R are present at higher levels in KS lesions in vivo than in surrounding normal dermis; and IL-6 can promote the growth of KS cells in vitro (18, 33). Furthermore, IL-6 has also been implicated in the development of MCD (with which KS is associated), with high levels of IL-6 being detected in involved tissues (27). For PEL, a recent report has noted that hIL-6 is produced by and appears to act as an intracrine mitogenic factor in at least two cell lines (4). Paracrine mechanisms effecting cell growth have been noted for HHV-8-infected endothelial cell cultures, in which a minority of HHV-8 cells are able to support the rapid proliferation of uninfected endothelial cells (19). These kinds of findings raise the possibility that the HHV-8-specified vIL-6 protein is relevant in influencing the development or manifestation of HHV-8-associated diseases. Characterization of the functional and mechanistic properties of vIL-6 is important for the assessment of its role in vivo.

It has been reported previously that HHV-8 vIL-6 encodes a functional protein displaying mitogenic properties in murine B9 cell cultures (36, 38) and that this function is at least partly dependent on the gp80 (IL-6R) component of the IL-6 receptor complex (38). More recent studies with human HepG2 hepatoma cells identified gp130 as a vIL-6 signal transducer, but the results of experiments in which anti-hIL-6R antibody
was used to block potential binding of vIL-6 to IL-6R had no effect on vIL-6 signalling through gp130 (35). The data presented here show that several acute-phase genes and C/EBP and STAT transcription factors can be induced by vIL-6 in Hep3B cells, that vIL-6 signalling in Hep3B cells utilizes gp130, that vIL-6 can signal through gp130 independently of IL-6R, and that IL-6R can enhance or enable vIL-6 signal transduction through gp130 or the variant gp130.PM5. Furthermore, the vIL-6 structure-function studies presented here identify amino acid residues important (and unimportant) for vIL-6 function, highlighting differences between vIL-6 and hIL-6.

The present data showing that IL-6R plays a role in vIL-6 signal transduction in transfected Hep3B cells is consistent with our previous investigations of the effects of vIL-6 on murine B9 cell growth, in which neutralizing antibody against murine IL-6R was able to partially inhibit vIL-6 mitogenic activity (38). Inhibitory effects of anti-hIL-6R antibody, in combination with anti-gp130 antibody, on vIL-6-stimulated human myeloma cell growth have also been reported (8). However, these investigators and Molden et al. (35) found no significant effects of anti-hIL-6R alone on vIL-6 function. The apparent inconsistencies between these findings and our previously reported results of murine B9 cell proliferation assays (38) may be the consequence of technical aspects of the experimental procedures used or of differences in the cell lines used for the various studies. For example, there may be differences in IL-6R-ligand contact sites between vIL-6 and hIL-6 resulting in ineffective blocking of vIL-6 binding by the particular “blocking” antibody used in the studies of Molden et al. (35) and Burger et al. (8), or there may be qualitative differences in hIL-6R and mIL-6R recognition by vIL-6. The data presented here show a small (two- to fivefold) positive effect of cotransfected hIL-6R on vIL-6 activity, as measured with an α₂-macroglobulin promoter-CAT reporter. Furthermore, using the gp130.PM5 variant, we were able to demonstrate clearly that IL-6R can play a role in vIL-6 signal transduction, since gp130.PM5 was fully functional with respect to IL-6R signalling in the presence of cotransfected IL-6R, but severely inhibited in its absence. The simplest interpretation of these combined results is that while IL-6 can recognize and signal through gp130 alone, IL-6R can also interact with vIL-6 and/or gp130 (wild-type and gp130.PM5) to stabilize functional-complex resolution. Resolution of the question whether vIL-6 and gp130 can indeed form functional complexes with IL-6R will require appropriate biochemical analyses to detect such ligand-receptor interactions directly.

Comparison of the amino acid sequence of vIL-6 with its sequenced endogenous counterparts has shown that it is considerably diverged from these homologues (36, 38, 39). The amino acid identity between vIL-6 and hIL-6 is approximately 25%. This degree of divergence of the primary structure is likely to affect the secondary and tertiary structures of the proteins, resulting in significant differences between vIL-6 and hIL-6. Indeed, evidence for such structural divergence is apparent from the results of the vIL-6 mutagenesis studies presented in Fig. 6 and Table 2. Only two of the mutations introduced into vIL-6 led to a significant decrease in vIL-6 activity, those at positions 167 (W to G) and 172 (A to P, within the context of a functionally neutral W-to-R mutation at position 167). Even mutations of the highly conserved third and fourth cysteine residues, previously reported to be important in hIL-6 for structural integrity and function, and of other residues with functionally important roles in hIL-6 (e.g., vIL-6 residues 88, 103 to 105, 183, and 189) had little or no effect on vIL-6 signalling. These differences between the vIL-6 and hIL-6 structure-function profiles could indicate different gp130 contact sites and reflect, at least in part, the IL-6R independence of vIL-6 signalling. Deletion of the C-terminal 10 amino acids of vIL-6, representing an “extension” relative to the endogenous IL-6 proteins, had no effect on vIL-6 function, demonstrating that this region of the protein is not involved in receptor recognition or in maintenance of overall protein structure.

Finally, a notable finding of the present study is that the concentration of vIL-6 required to mediate signal transduction, as measured by induction of STAT3, is comparable to the level of IL-6 required for signal transduction, as established clearly by many published reports. The minimum active concentration of vIL-6 used for STAT3 induction experiments presented in Fig. 3A was approximately 0.2 ng/ml, with maximum STAT3 induction being achieved with a vIL-6 concentration of around 2 ng/ml. This is in marked contrast to the approximately 10³-fold-higher concentration of bacterially expressed recombinant vIL-6 found to be active in our STAT3 induction assays (Fig. 3D) and reported to be required for support of B9 cell growth (8). The underlying basis for this difference in eukaryotically and bacterially expressed vIL-6 specific activity is unclear but could relate to the lack of appropriate posttranslational modification and/or the presence of the N-terminal polyhistidine tract in the recombinant vIL-6 proteins. Such a situation would distinguish vIL-6 from various cellular IL-6 proteins whose specific activities appear not to be dependent on posttranslational modifications and specific N-terminal processing.

The data presented in this report extend the results of previous studies (8, 35, 38) into the types and mechanistic basis of vIL-6 activity by identifying transcription factors activated by vIL-6 in Hep3B human hepatocarcinoma cells, providing a detailed structure-function analysis of vIL-6, identifying a region (possibly representing a vIL-6–gp130 contact site) within the E-F cytokine binding loop of gp130 that is required for vIL-6 function in the absence of IL-6R, and demonstrating the involvement of IL-6R in vIL-6 signal transduction. We hope that these data will prove useful in contributing to an overall understanding of vIL-6 function in vivo and to the development of methods, possibly employing vIL-6-receptor binding-site peptide sequences, to specifically block the function of vIL-6, an HHV-8 cytokine that may influence viral pathogenesis.

ACKNOWLEDGMENTS

We are grateful to M. Narazaki and T. Kishimoto for supplying the pEFBOS–hIL-6R and pEFBOS–gp130 expression vectors. This work was supported by R55 and R01 grants CA76445 from the National Institutes of Health.

REFERENCES


Clogston, C. L., T. C. Boone, B. C. Crandall, E. A. Mendiaz, and H. S. Lu.


Hamanncher, L., A. J. Simpson, and E. C. Nice. 1996. Interleukin-6 (IL-6) partial antagonist (Q159E, T162P) IL-6 interacts with the IL-6 receptor and gp130 but fails to induce a stable hexasmeric receptor complex. J. Biol. Chem. 271:5464–5473.


Mizushima, S., and S. Nagata. 1998. The lipopolysaccharide-binding protein is a secretory class I active protein whose gene is transcriptionally activated by APRF/STAT-3 and other cytokine-inducible